Regulatory Pfizer, Arvinas join SERD club with Veppanu approval PharmaphorumArvinas and Pfizer's Veppanu is the first PROTAC - and third oral SERD for breast cancer - to be approved by the FDA.OncologyRead full story pharminent May 4, 2026 (Last updated: May 4, 2026) Pharmaphorum Arvinas and Pfizer’s Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA. Oncology Read full story Post navigation Previous: Novartis unveils North Carolina API plant as final piece of $23B US expansionNext: Novo Nordisk to launch Ozempic for type 2 diabetes in US Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026